India, April 17 -- Shares of Adagio Medical Holdings, Inc. (ADGM) soared over 150% on Thursday morning after the company received FDA Breakthrough Device designation for the vCLASTM Cryoablation System.
ADGM is currently trading at $2.2700, up $1.3959 or 159.6957%, on a huge volume of 41 million shares, above average volume of 122 thousand, on the Nasdaq. The stock opened its trading at $0.9502 after closing Wednesday at $0.8741. The stock has traded between $0.6250 and $9.3400 in the past 52-week period.
FDA's Breakthrough Device designation program allows for priority review of Ablation Technology for Ventricular Tachycardia
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Adagio's vCLASTM Cryoablat...